Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CORALVILLE, Iowa, March 27, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett, Ph.D., Senior Director, Scientific Affairs, will present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum being held March 27, 2017, at the New York Academy of Sciences.
Details of KemPharm's presentation are as follows:
| Event: | 2nd Annual Neuroscience Biopartnering and Investment Forum | |
| Date: | Monday, March 27, 2017 | |
| Time: | 3:20 p.m. ET | |
| Location: | New York Academy of Sciences 7 World Trade Center 250 Greenwich St., 40th Floor (D Elevator Bank) New York, NY 10007 | |
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
